Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 protection against pneumococcal infection in children with type 1 diabetes
ISRCTN40519356Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by University of Oxford. Primary endpoint: Proportion of children with vaccine pneumococcal serotype-specific antibody concentration at 12 months. Started Aug 2013; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ISRCTN40519356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40519356.